Compound library/Primary-source evidence guide

MOTS-c

Separating endogenous-peptide and laboratory findings from unproven treatment claims

MOTS-c is a mitochondrial-derived peptide studied in cells, animals, and human physiology research. It is not an FDA-approved drug. A phase 2a treatment trial began in 2026, so efficacy and safety claims for injected MOTS-c currently run ahead of completed therapeutic human evidence.

Editorial status

This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .

It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.

Product and regulatory distinctions

A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.

MOTS-c free base and MOTS-c acetate

No FDA-approved MOTS-c drug product. FDA's 2026 review weighed against adding the substances to the 503A Bulks List because characterization and human safety/effectiveness information were inadequate.

Current source

Investigational injected MOTS-c

A randomized phase 2a trial in adults with prediabetes and overweight or obesity is ongoing; trial registration is not evidence of benefit.

Current source

Claim-by-claim evidence map

Each finding is tied to the population and product actually studied. Trial results are not personal predictions.

Observational human evidence

Exercise studies detect endogenous MOTS-c in humans, but do not test injected MOTS-c as a treatment.

Population
Small controlled exercise studies in healthy adults with blood and, in some studies, skeletal-muscle sampling.
Finding
Researchers reported changes in circulating or tissue MOTS-c measurements in relation to exercise.
Limits
Measuring a naturally occurring peptide during exercise cannot establish that a manufactured injectable improves performance, metabolism, recovery, or longevity.
Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humansMOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical declineMOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency
Unsupported or anecdotal

The first listed phase 2a therapeutic study is testing, not confirming, metabolic efficacy.

Population
Planned enrollment of 120 adults with prediabetes and overweight or obesity.
Finding
The registered randomized, double-blind study compares 12 weeks of investigational MOTS-c with placebo and has an estimated primary completion in 2027.
Limits
No treatment results are posted. Study rationale and planned endpoints must not be described as demonstrated outcomes.
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745)
Unsupported or anecdotal

FDA found insufficient information to assess the proposed compounded drug uses and their risks.

Population
FDA evaluation of nominated MOTS-c bulk drug substances.
Finding
FDA reported no identified human administration information in its review and highlighted unknown immunogenicity and product-characterization risks.
Limits
FDA's conclusion describes missing evidence, not a quantified rate of harm; newer trials may change the evidence base when completed and published.
FDA Briefing Document: MOTS-c-related bulk drug substances503A Bulk Drug Substances Categories

What this evidence does not answer

  • No completed randomized therapeutic trial currently establishes benefit for insulin sensitivity, weight loss, athletic performance, recovery, or longevity.
  • Endogenous MOTS-c measurements do not define the pharmacology or safety of manufactured products.
  • Long-term human safety, immunogenicity, product identity, purity, and route-specific risks remain uncertain.

Useful information to organize between visits

  • Exact product name, route, seller or dispenser, and stated ingredients
  • Lot or batch identifier and any certificate tied to that lot
  • Exposure date and symptoms with onset, severity, and duration
  • Relevant clinician-ordered metabolic or safety results
  • Suspected adverse events to discuss with a clinician and report when appropriate

Questions to bring to a clinician or pharmacist

  1. 1.Is any MOTS-c product FDA approved for the claimed purpose?
  2. 2.Are completed human treatment results available, rather than animal or exercise-association findings?
  3. 3.What is known about identity, sterility, impurities, and immunogenicity for this product?
  4. 4.How should symptoms or a suspected adverse event be assessed and reported?

Primary sources

  1. FDA Briefing Document: MOTS-c-related bulk drug substancesU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
  2. 503A Bulk Drug Substances CategoriesU.S. Food and Drug Administration · Published 2024 · Accessed July 12, 2026
  3. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745)ClinicalTrials.gov · Published 2026 · Accessed July 12, 2026
  4. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humansAmerican Journal of Physiology via PubMed · Published 2021 · Accessed July 12, 2026
  5. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical declineNature Communications via PubMed · Published 2021 · Accessed July 12, 2026
  6. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiencyFree Radical Biology and Medicine via PubMed · Published 2026 · Accessed July 12, 2026

Turn scattered notes into a useful treatment history

Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.

Start tracking free